BeOne Medicines (NASDAQ:ONC) Stock, Options inhabituelles

BeiGene

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Aperçu

Actualités

Gains

Options

Orientation

Évaluations des analystes

Transactions internes

Intérêt court

Rapport sur les stocks

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

Comments

BeOne Medicines Options Inhabitueles

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Benzinga

Benzinga

Benzinga

Comments

BeOne Medicines Options Inhabitueles

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL